BACKGROUND:Ventilatory efficiency, right ventricular (RV) function, and secondary pulmonary hypertension are each prognostic indicators in patients with heart failure due to left ventricular systolic dysfunction, but the relationships among these variables have not been comprehensively investigated. In this study, we hypothesized that inefficient ventilation during exercise, as defined by an abnormally steep relationship between ventilation and carbon dioxide output (Ve/Vco(2) slope), may be a marker of secondary pulmonary hypertension and RV dysfunction in heart failure. METHODS AND RESULTS: A cohort of patients with systolic heart failure (mean+/-SD age, 58+/-13 years; left ventricular ejection fraction, 0.27+/-0.05; peak oxygen uptake, 11.2+/-3.2 mL kg(-1) min(-1)) underwent incremental cardiopulmonary exercise testing with simultaneous hemodynamic monitoring and first-pass radionuclide ventriculography before and after 12 weeks of treatment with sildenafil, a selective pulmonary vasodilator, or placebo. Ve/Vco(2) slope was positively related to rest and exercise pulmonary vascular resistance (R=0.39 and R=0.60, respectively) and rest pulmonary capillary wedge pressure (R=0.49, P<0.005 for all) and weakly indirectly related to peak exercise RV ejection fraction (R=-0.29, P=0.03). Over the 12-week study period, Ve/Vco(2) slope fell 8+/-3% (P=0.02) with sildenafil and was unchanged with placebo. Changes in Ve/Vco(2) slope correlated with changes in exercise pulmonary vascular resistance (R=0.69, P<0.001) and rest and exercise RV ejection fraction (R=-0.58 and -0.40, respectively, both P<0.05). CONCLUSIONS: In patients with systolic heart failure and secondary pulmonary hypertension, ventilatory efficiency is closely related to RV function and pulmonary vascular tone during exercise.
RCT Entities:
BACKGROUND: Ventilatory efficiency, right ventricular (RV) function, and secondary pulmonary hypertension are each prognostic indicators in patients with heart failure due to left ventricular systolic dysfunction, but the relationships among these variables have not been comprehensively investigated. In this study, we hypothesized that inefficient ventilation during exercise, as defined by an abnormally steep relationship between ventilation and carbon dioxide output (Ve/Vco(2) slope), may be a marker of secondary pulmonary hypertension and RV dysfunction in heart failure. METHODS AND RESULTS: A cohort of patients with systolic heart failure (mean+/-SD age, 58+/-13 years; left ventricular ejection fraction, 0.27+/-0.05; peak oxygen uptake, 11.2+/-3.2 mL kg(-1) min(-1)) underwent incremental cardiopulmonary exercise testing with simultaneous hemodynamic monitoring and first-pass radionuclide ventriculography before and after 12 weeks of treatment with sildenafil, a selective pulmonary vasodilator, or placebo. Ve/Vco(2) slope was positively related to rest and exercise pulmonary vascular resistance (R=0.39 and R=0.60, respectively) and rest pulmonary capillary wedge pressure (R=0.49, P<0.005 for all) and weakly indirectly related to peak exercise RV ejection fraction (R=-0.29, P=0.03). Over the 12-week study period, Ve/Vco(2) slope fell 8+/-3% (P=0.02) with sildenafil and was unchanged with placebo. Changes in Ve/Vco(2) slope correlated with changes in exercise pulmonary vascular resistance (R=0.69, P<0.001) and rest and exercise RV ejection fraction (R=-0.58 and -0.40, respectively, both P<0.05). CONCLUSIONS: In patients with systolic heart failure and secondary pulmonary hypertension, ventilatory efficiency is closely related to RV function and pulmonary vascular tone during exercise.
Authors: Ross Arena; Jonathan Myers; Joshua Abella; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Marco Guazzi Journal: Circulation Date: 2007-04-23 Impact factor: 29.690
Authors: Gregory D Lewis; Justine Lachmann; Janice Camuso; John J Lepore; Jordan Shin; Maryann E Martinovic; David M Systrom; Kenneth D Bloch; Marc J Semigran Journal: Circulation Date: 2006-12-18 Impact factor: 29.690
Authors: A Matsumoto; S Momomura; S Sugiura; H Fujita; T Aoyagi; M Sata; M Omata; Y Hirata Journal: Ann Intern Med Date: 1999-01-05 Impact factor: 25.391
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Robert L Bard; Brenda W Gillespie; Nicholas S Clarke; Timothy G Egan; John M Nicklas Journal: J Heart Lung Transplant Date: 2006-03-23 Impact factor: 10.247
Authors: Gregory D Lewis; Ravi Shah; Khurram Shahzad; Janice M Camuso; Paul P Pappagianopoulos; Judy Hung; Ahmed Tawakol; Robert E Gerszten; David M Systrom; Kenneth D Bloch; Marc J Semigran Journal: Circulation Date: 2007-09-04 Impact factor: 29.690
Authors: Steven Hsu; Brian A Houston; Emmanouil Tampakakis; Anita C Bacher; Parker S Rhodes; Stephen C Mathai; Rachel L Damico; Todd M Kolb; Laura K Hummers; Ami A Shah; Zsuzsanna McMahan; Celia P Corona-Villalobos; Stefan L Zimmerman; Fredrick M Wigley; Paul M Hassoun; David A Kass; Ryan J Tedford Journal: Circulation Date: 2016-05-11 Impact factor: 29.690
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie Journal: Expert Rev Respir Med Date: 2011-04 Impact factor: 3.772
Authors: Ravi Shah; Ashish Yeri; Avash Das; Amanda Courtright-Lim; Olivia Ziegler; Ernest Gervino; Jeffrey Ocel; Pablo Quintero-Pinzon; Luke Wooster; Cole Shields Bailey; Kahraman Tanriverdi; Lea M Beaulieu; Jane E Freedman; Ionita Ghiran; Gregory D Lewis; Kendall Van Keuren-Jensen; Saumya Das Journal: Am J Physiol Heart Circ Physiol Date: 2017-09-15 Impact factor: 4.733